Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study
Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study is a paper indexed in PICO Portal from OpenAlex.
How many citations does Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study have?
Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study has 1 citations in the OpenAlex counts PICO Portal stores.
When was Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study published?
Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study has 2025 year in the PICO Portal index.
What is the open-access status of Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study?
Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study has closed oa status in the PICO Portal index.
What is the DOI of Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study?
The DOI for Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study is on the source record.
What is the OpenAlex record for Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study?
The OpenAlex for Efficacy of Benralizumab in Reducing Cough Frequency and Improving Health-Related Quality of Life in Patients With Severe Eosinophilic Asthma in Asia: A Post-hoc Analysis of the Phase 3 Miracle Study is on the source record.